Literature DB >> 15560063

Clinical application of hepatitis C virus genotyping and quantitation.

M W Fried1.   

Abstract

Genotyping and quantitation of hepatitis C virus have provided great insights into the pathogenesis of chronic hepatitis C. The assays that are currently available for characterizing HCV remain powerful research tools that will be invaluable in future studies of the next generation of antiviral agents for the treatment of hepatitis C in much the same way that they have provided information about the effectiveness of interferon. Retrospective studies have demonstrated that HCV genotype and viral burden may play some role in disease progression and response to therapy. However, their utility in daily clinical practice in making decisions about treatment regimens or monitoring therapy in an individual patient remains difficult to define. As newer, more effective treatment strategies evolve (longer duration of treatment, combination therapy), previously identified predictors of disease severity or response to treatment may no longer be applicable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 15560063     DOI: 10.1016/s1089-3261(05)70326-3

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  3 in total

1.  Evaluation of molecular diagnostic assays for fungal infections.

Authors:  Gary W Procop
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

2.  Performance characteristics of a quantitative, homogeneous TaqMan RT-PCR test for HCV RNA.

Authors:  J Kleiber; T Walter; G Haberhausen; S Tsang; R Babiel; M Rosenstraus
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

3.  Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.

Authors:  S C Lee; A Antony; N Lee; J Leibow; J Q Yang; S Soviero; K Gutekunst; M Rosenstraus
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.